Acquired C1 esterase inhibitor deficiency, also referred to as acquired angioedema (AAE), is a rare medical condition that presents as body swelling that can be life-threatening and manifests due to another underlying medical condition. The acquired form of this disease can occur from a deficiency or abnormal function of the enzyme C1 esterase inhibitor (C1-INH). This disease is also abbreviated in medical literature as C1INH-AAE. This form of angioedema is considered acquired due to its association with lymphatic malignancies, immune system disorders, or infections. Typically, acquired angioedema presents later in adulthood, in contrast to hereditary angioedema which usually presents from early childhood and with similar symptoms.
Acquired angioedema is usually found after recurrent episodes of swelling and can in some cases take several months to diagnose. Diagnosis usually consists of medical evaluation in addition to laboratory testing. Laboratory evaluation includes complement studies, in which typical cases demonstrate low C4 levels, low C1q levels, and normal C3 levels. Determining the etiology, or cause, of acquired angioedema is often helpful in providing appropriate management of AAE.
Management of AAE usually includes treating any underlying disorder that could be responsible for the condition. Additionally, symptom management is important, especially in cases that are life-threatening. There are medications available to treat AAE, which are focused on replacing deficient levels of C1-INH or abnormal C1-INH enzymes. There are some cases of partial improvement and full resolution with treatment of the underlying medical problems contributing to AAE.
Epidemiology
It is estimated that the worldwide prevalence of AAE ranges from 1 person in every 10,000 people are affected to 1 case in every 150,000 people. However, it is thought that this disease prevalence could be higher due to diagnostic oversight and the shared symptoms of acquired angioedema with similar diseases. This disease tends to affect males and females equally. Additionally, individuals with acquired angioedema usually develops symptoms in their fourth decade of life or older. Of note, Saini reports the difficulty of diagnosing angioedema accurately due to certain challenges. These obstacles include the lack of awareness about angioedema presentation and potentially higher than expected worldwide prevalence. More challenges include the similarities to paraneoplastic disorders that often require higher priority of care, the evolution of symptoms over time, and mild cases might be attributed to medication use or allergic reactions from an individual's existing medical history. As a result, accurate diagnosis of AAE can take several months, which can delay targeted and specific treatment.
Causes
There are various disease comorbidities associated with acquired C1 esterase inhibitor deficiency, including:
Lymphoproliferative disorders and lymphatic malignancies
Lymphoproliferative disorders, such as monoclonal gammopathy of undetermined significance (MGUS) and non-Hodgkin lymphoma are associated with acquired angioedema. In cohort studies, MGUS is considered one of the most common disorders associated with AAE. MGUS is a premalignant plasma cell disorder that is associated with bone marrow pathologic changes leading to abnormal production of M protein that can progress to other hematologic diseases. Additionally, through retrospective case studies performed in France, Gobert et al. found that non-Hodgkin lymphoma was associated with 48% of cases in a sample size of 92 cases of acquired angioedema. Multiple myeloma (MM) is a malignant plasma cell disorder that progresses from MGUS. MM is characterized by elevated monoclonal paraprotein in addition to end organ damage, such as kidney failure. Lymphoplasmacytic lymphoma (also known as Waldenström macroglobulinemia) is a B cell malignancy with hematologic changes that affect the lymphatic system. Some of the clinical manifestations seen in this lymphoma are anemia, hyperviscosity syndrome, and neuropathy.